Trends in the use and role of biomarkers in phase I oncology trials.
about
What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer TherapiesUse of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer.Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.Research biopsies in the context of early phase oncology studies: clinical and ethical considerations.Improving access to novel agents for childhood leukemia.Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patientAnalysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.New cast for a new era: preclinical cancer drug development revisited.Clinical trial design for testing the stem cell model for the prevention and treatment of cancer.Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review)Biomarkers in early cancer drug development: limited utility.Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.HER3 mRNA as a predictive biomarker in anticancer therapy.Early oncology clinical trial design in the era of molecular-targeted agents.Preclinical development of molecular-targeted agents for cancer.Dose-toxicity models in oncology.Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis.Improving the outcomes: developing cancer therapeutics.Drug development and clinical trials--the path to an approved cancer drug.Overcoming implementation challenges of personalized cancer therapy.Biopsies: next-generation biospecimens for tailoring therapy.Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.The use of circulating biomarkers in early clinical trials in patients with cancer.The changing landscape of phase I trials in oncology.Use of research biopsies in clinical trials: are risks and benefits adequately discussed?Translation of anticancer efficacy from nonclinical models to the clinic.Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.Burdensome Research Procedures in Trials: Why Less Is More.Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.Underreporting of Research Biopsies from Clinical Trials in Oncology.The inverted pyramid of biomarker-driven trials.A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.
P2860
Q33775647-F29EBEFF-A570-4280-BD27-C224C99BD46CQ33985780-9F5FCFF6-85BE-4D33-A2C9-CDDF2A6C0F43Q35148262-838DFE82-709F-488F-AB8E-55BAE29D8B54Q35287729-9B9A70BF-6595-4C47-B940-EFDD21F7CD2CQ35569312-5350E248-F45B-467D-A8A6-02BE512AF588Q35688742-73134167-8B83-4389-9794-3C98FF958025Q36266655-F48BF97A-E275-4C80-8CCA-408BDDC41C86Q36732058-F54EBA4E-9CB6-40F5-84B7-FDDF0041537AQ36914483-9691A2C8-13CD-4B3E-AF60-FF25BB666F6BQ37111197-3FF4E2E9-28C6-4E38-B523-49B8E0CDCED9Q37123902-7A61FE03-3725-4EE9-86D5-B93C201AF436Q37132809-293E9969-C2DB-4B35-BC4C-B9EA7FFAA202Q37260992-AAE43535-C349-4770-90BA-E0FAFF5CC5F1Q37371586-00A8C49A-D406-430E-9BED-936F5498B4D5Q37552670-41B967DE-1C35-474F-85AF-FA3EA038110BQ37778843-EE0EEECC-105F-48E8-8B9E-D259FAB9481EQ37783623-3721CA05-571B-4983-BB5B-00B166D84DC6Q37816960-9D8B7F48-034C-4599-B8AF-CC24501051CFQ37829437-1F5560BE-6462-4782-86BF-F31376D827B3Q37862749-2A34BD3B-E41E-4E75-B604-E5AF3764361DQ37965556-CE54274E-A79C-45C6-9E45-88A33ACF9AAEQ37988792-1BCAC212-6DC9-44C8-A203-1E2CE2C5F1B6Q38031117-B285B6E8-031E-4C12-BC7B-AAAE686F2C76Q38116896-50C72399-11C2-4181-B7DB-AB5F7186CC22Q38586993-5BB81EC6-C7A4-47D8-89BE-F1EDF06043FDQ38600479-26959698-EB42-4063-B8C1-907AE7CA3146Q38629203-158883F0-05C8-412E-B20F-DA7C1D931A10Q41264496-A168B58B-5B28-4E6E-BC56-E166C4722380Q42854744-DBC43DE0-0A64-474A-8B6D-FC4C3CED2103Q44100364-B61621FB-0FF3-4147-B9F0-92AFDB6F881FQ47926951-2CC85F0E-DEFE-4CC3-8F2B-58A26E212F28Q50422614-02B7161F-2662-4CC1-AD17-4B93DDCA2829Q50517279-1D44A388-AA51-4A93-B4A7-AAF00DBAED29Q51689988-340525B1-5493-43A0-A022-FA6A8B574EA1Q53201697-0BE6EAE1-5604-48CD-AA28-302D34C805AE
P2860
Trends in the use and role of biomarkers in phase I oncology trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Trends in the use and role of biomarkers in phase I oncology trials.
@en
Trends in the use and role of biomarkers in phase I oncology trials.
@nl
type
label
Trends in the use and role of biomarkers in phase I oncology trials.
@en
Trends in the use and role of biomarkers in phase I oncology trials.
@nl
prefLabel
Trends in the use and role of biomarkers in phase I oncology trials.
@en
Trends in the use and role of biomarkers in phase I oncology trials.
@nl
P2093
P1476
Trends in the use and role of biomarkers in phase I oncology trials.
@en
P2093
Bernardo H L Goulart
Bruce A Chabner
Homer H Pien
Jeffrey W Clark
Stan N Finkelstein
Thomas G Roberts
P304
P356
10.1158/1078-0432.CCR-06-2860
P407
P433
P577
2007-11-01T00:00:00Z